Zydus Cadila gets USFDA nod for migraine drug
Zydus Cadila has received final approval from the US health regulator to market Zolmitriptan tablets, used to relieve headache, pain, and other migr12-07-2018
12-07-2018
Statement Of Investor Complaints For The Quarter Ended June 2018
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Upen ShahDesignation :- Company Secretary and Compliance Officer12-07-2018
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Zolmitriptan Tablets USP12-07-2018
Shareholding for the Period Ended June 30, 2018
Cadila Healthcare Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2018. For more details, kindly Click here09-07-2018
Zydus Cadila gets USFDA's tentative nod to market Deferasirox tablets
The tablet is used to treat high levels of iron in the body caused by multiple blood transfusions07-07-2018
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Cadila Healthcare Limited has informed the Exchange regarding a press release dated July 07, 2018, titled "Zydus receives tentative approval from the USFDA for Deferasirox Tablets for Oral Suspension."07-07-2018
CSIR-IMTECH inks pact with Zydus Cadila
Drug firm Zydus Cadila today said it has inked an agreement with the Council of Scientific and Industrial Research (CSIR) - Institute of Microbial T05-07-2018
Announcement under Regulation 30 (LODR)-Press Release / Media Release
CSIR-IMTECH in partnership with Zydus Cadila for development of newer drugs for drug-resistant infectious diseases05-07-2018
Zydus Cadila gets USFDA nod to market 2 drugs
Zydus Cadila has received final approval from the US health regulator to market Nifedipine extended-release tablets and Cholestyramine for oral susp03-07-2018
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Cadila Healthcare Limited has informed the Exchange regarding a press release dated July 03, 2018, titled "Zydus receives final approval from the USFDA for Nifedipine Extended-Release Tablets USP and Cholestyramine for Oral Suspension USP."03-07-2018